GSK Near-Term Pipeline Relies On Line Extensions; “Wall” Of NMEs To Come
Executive Summary
GlaxoSmithKline is relying primarily on line extensions and supplemental indications to fill its nearer-term pipeline before the effect of a revamped R&D effort kicks in
You may also be interested in...
GSK Is Not Aventis’ “White Knight”; 2004 Will Be A Transition Year
GlaxoSmithKline will not make a "white knight" bid for Aventis, GSK said during its Feb. 12 year-end earnings presentation
GSK Is Not Aventis’ “White Knight”; 2004 Will Be A Transition Year
GlaxoSmithKline will not make a "white knight" bid for Aventis, GSK said during its Feb. 12 year-end earnings presentation
GSK Lamictal monotherapy for seizures
GlaxoSmithKline's Lamictal (lamotrigine) approved by FDA Jan. 14 for use as monotherapy in the treatment of partial seizures in patients 16 years and older. Originally approved in December 1996 as adjunctive therapy in the treatment of partial seizures in adults with epilepsy, Lamictal has been part of GSK's plan to fill in its nearer-term pipeline through line extensions (1"The Pink Sheet" Dec. 15, 2003, p. 29)...